$country= Comparative statistics by cancer registry - SurvCan

Comparative statistics by cancer registry

Registry: Comparative statistics by cancer site

Table1: Data quality indices - Proportion (%) of histologically verified and death certificate only cases, number and proportion of included and excluded cases by site

(Izmir, Turkey, 1995-1997 cases followed-up until 2003)

Click on cancer site (ICD-10 code) for comparison
%No. of excluded casesIncluded cases
SiteICD-10Total registeredHVDCODCONo. follow-upOthersTotal%No.%
C18Colon38084.20.003692.437197.6
C19-20Rectum34992.80.003251.434498.6
C32Larynx48195.60.001230.647899.4
C50Breast134695.60.00611171.3132998.7
C53Cervix24898.00.000220.824699.2
C56Ovary23298.30.000220.923099.1
C67Urinary bladder57191.20.003250.956699.1
C81Hodgkin lymphoma85100.00.000000.085100.0
C82-85+C96Non-Hodgkin lymphoma350100.00.001561.734498.3
C90Multiple myeloma79100.00.000000.079100.0
C91Lymphoid leukaemia161100.00.000000.0161100.0
C92-94Myeloid leukaemia149100.00.001010.714899.3


Other tables available for this registry:
- Table1: Data quality indices - Proportion (%) of histologically verified and death certificate only cases, number and proportion of included and excluded cases by site (Izmir, Turkey, 1995-1997 cases followed-up until 2003)
- Table2a: Number and proportion of cases with complete/incomplete follow-up and median follow-up (in months) by site (Izmir, Turkey, 1995-1997 cases followed-up until 2003)
- Table3: Comparison of 1-, 3- and 5-year absolute and relative survival and 5-year age-standardized relative survival (ASRS) by site (Izmir, Turkey, 1995-1997 cases followed-up until 2003)
- Table4: Site-wise number of cases, 5-year absolute and relative survival by sex and relative survival by age group (Izmir, Turkey, 1995-1997 cases followed-up until 2003)
- Table5b: Proportion (%) of cases and 5-year absolute survival by extent of disease and site (Izmir, Turkey, 1995-1997)




Registry chapter:


Consult the chapter in Cancer survival in developping countries (Volume II)